EFFICACY OF NIFEKALANT HYDROCHLORIDE ON THEMANAGEMENT OF LIFE-THREATENING VENTRICULARTACHYARRHYTHMIAS IN PATIENTS WITH NON-ISCHEMICCARDIOMYOPATHY.

摘要

We investigated the effect of nifekalant on VTs with non-ischemic cardiomyopathy. Ten patients with non-ischemic cardiomyopathy and VTs (male 9, female I, 60+-9 yo, LVEF 37+-16%) were included in this study. Underlying heart diseases were DCM (n=4), HCM (n=4), ARVC (n=l) and cardiac sarcoidosis (n=l). Nifekalant was administered to suppress the frequent recurrence of VTs. QT and QTc prolonged after nifekalant significantly (p=0.001), respectively. In 6 of 10 patients nifekalant completely suppressed the recurrence of VTs. In other 3 patients, nifekalant decreased the frequency of VTs. In another one, antitachycardia pacing from his ICD could easily terminate VT after nifekalant. Nifekalant was continued for 16+-10 days. After nifekalant discontinuation, it was replaced by the combination of amiodarone and B-blocking agent in 4 patients and by sotalol in 5 patients. Another one patient was treated by catheter ablation. (Conclusion) Nifekalant administration was safe and effective to control recurrent VTs associated with non-ischemic cardiomyopathy.